1,726
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Tumor infiltrating lymphocytes: current pathways to a standard biomarker in breast cancer

, &
Pages 1299-1301 | Received 22 Apr 2021, Accepted 28 Jun 2021, Published online: 24 Jul 2021
 

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

A reviewer on this manuscript has received travel support from Pfizer, Novartis, Amgen and Daiichi Sankyo. The remaining reviewers have no other relevant financial relationships or otherwise to disclose.

Additional information

Funding

WT Tran and FI Lu have received grant funding from the Tri-Council (CIHR) Government of Canada’s New Frontiers in Research Fund (NFRF, Grant # NFRFE-2019-00193). WT Tran has also received funding from the Terry Fox Research Institute (TFRI, Grant #1083), the Women’s Health Golf Classic Foundation Fund, and the CAMRT Research Grant (Grant #2021-01).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.